Malignant Thyroid Gland Neoplasm
Associated Genetic Biomarkers
NCI Definition: A primary or metastatic malignant neoplasm affecting the thyroid gland. 
Malignant thyroid gland neoplasms most frequently harbor alterations in BRAF, RET, TP53, NRAS, and CDKN2A .
BRAF Mutation, BRAF Exon 15 Mutation, BRAF Codon 600 Missense, BRAF V600E, and NRAS Mutation are the most common alterations in malignant thyroid gland neoplasm .
There are 5 clinical trials for malignant thyroid gland neoplasm, of which 1 is open and 4 are completed or closed. Of the trials that contain malignant thyroid gland neoplasm as an inclusion criterion, 2 are phase 1 (0 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (1 open).
CD276, CTAG1A, and CTAG1B are the most frequent gene inclusion criteria for malignant thyroid gland neoplasm clinical trials .
Anti-ny-eso-1 tcr lv-transduced autologous t-cells taest16001, cyclophosphamide, and enoblituzumab are the most common interventions in malignant thyroid gland neoplasm clinical trials.
Significant Genes in Malignant Thyroid Gland Neoplasm
HRAS is altered in 5.05% of malignant thyroid gland neoplasm patients .
HRAS is an inclusion eligibility criterion in 1 clinical trial for malignant thyroid gland neoplasm, of which 0 are open and 1 is closed. Of the trial that contains HRAS status and malignant thyroid gland neoplasm as inclusion criteria, 1 is phase 2 (0 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.